Literature DB >> 10141767

Implementation issues in disease management programs: a pharmaceutical company perspective.

R A Browne1.   

Abstract

Eli Lilly, a pharmaceutical manufacturer, recently established a disease management subsidiary. The author, one of the key forces behind the new venture, provides a how-to based on the company's experiences in developing Integrated Disease Management, Inc. His views, from the pharmaceutical company perspective, may also be applicable to any organization seeking to climb into the red-hot arena of disease management.

Mesh:

Year:  1995        PMID: 10141767

Source DB:  PubMed          Journal:  Med Interface        ISSN: 0896-4831


  1 in total

1.  Determinants of HMO formulary adoption decisions.

Authors:  David Dranove; Edward F X Hughes; Mark Shanley
Journal:  Health Serv Res       Date:  2003-02       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.